Page last updated: 2024-08-24

3-iodobenzylguanidine and Neoplasm Metastasis, Unknown Primary

3-iodobenzylguanidine has been researched along with Neoplasm Metastasis, Unknown Primary in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ash, S; Bar Shalom, R; Bar-Deroma, R; Ben Barak, A; Berniger, A; Golan, H; Goldstein, G; Houri, H; Kuten, A; Nevelsky, A; Nevo, N; Toren, A; Waldman, D; Weyl Ben-Arush, M; Yaniv, I1
Servaes, S; Zhang, W; Zhuang, H1
Boot, H; Hoefnageli, CA; Taal, BG; Valdés Olmos, RA; Zuetenhorst, JM1
Bussy, E; Jacob, T; Lescout, JM1
Arndt, JW; Jeurissen, F; Kagie, MJ; van Luijk, IF1
Bagni, B; Orsolon, P1

Trials

1 trial(s) available for 3-iodobenzylguanidine and Neoplasm Metastasis, Unknown Primary

ArticleYear
Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease.
    Nuclear medicine communications, 2002, Volume: 23, Issue:8

    Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Appendiceal Neoplasms; Bone Neoplasms; Carcinoid Tumor; False Negative Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Octreotide; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Rectal Neoplasms; Technetium Tc 99m Medronate

2002

Other Studies

5 other study(ies) available for 3-iodobenzylguanidine and Neoplasm Metastasis, Unknown Primary

ArticleYear
Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    The Israel Medical Association journal : IMAJ, 2013, Volume: 15, Issue:1

    Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Infant; Male; Neoplasm Staging; Neoplasms, Unknown Primary; Neuroblastoma; Palliative Care; Retrospective Studies; Treatment Outcome

2013
Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:8

    Topics: 3-Iodobenzylguanidine; Bone Neoplasms; Child, Preschool; Fluorodeoxyglucose F18; Humans; Male; Neoplasms, Unknown Primary; Neuroblastoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

2016
Malignant diaphragmatic pheochromocytoma.
    Clinical nuclear medicine, 2002, Volume: 27, Issue:11

    Topics: 3-Iodobenzylguanidine; Adult; Diaphragm; Humans; Liver Neoplasms; Male; Neoplasms, Unknown Primary; Pheochromocytoma; Postoperative Care; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Thoracic Neoplasms

2002
Intraoperative detection of carcinoid tumor of the ovary by gamma probe.
    Clinical nuclear medicine, 2004, Volume: 29, Issue:6

    Topics: 3-Iodobenzylguanidine; Adult; Carcinoid Tumor; Female; Gamma Cameras; Gynecologic Surgical Procedures; Humans; Intraoperative Care; Neoplasms, Unknown Primary; Ovarian Neoplasms; Radionuclide Imaging; Radiopharmaceuticals

2004
131I MIBG/111In octreotide mismatch in a patient with liver metastases secondary to a carcinoid of unknown origin.
    Minerva endocrinologica, 1995, Volume: 20, Issue:2

    Topics: 3-Iodobenzylguanidine; Adult; Contrast Media; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Liver Neoplasms; Male; Neoplasms, Unknown Primary; Octreotide; Tomography, Emission-Computed

1995